Hidradenitis Suppurativa: The Search Continues With Hope on The Horizon Through Diet Changes

TrialSite News recently published an original analysis titled “Hidradenitis Suppurativa Trials Analysis” which received considerable interest from our readers. As we analyzed the traffic, in part by engaging via social media where we have connected with Hidradenitis Suppurativa (HS) patients, it became clear to us that there was a great disappointment. Our analysis covered most of the clinical trials currently underway (all phases) and most of the investigational drugs constituting biologics (e.g. monoclonal antibodies, etc.). Although the scientific and medical literature clearly demonstrates that this class of drug can have a positive impact in reducing HS symptoms, there are well-known side effects—some of which can be severe.

We sensed from several interactions with the HS community that many who visit TrialSite News are seeking more information. They need to understand what other options exist. Is there something else that could help them that isn’t a monoclonal antibody based biologic drug with the potential for debilitating side effects?  Unfortunately, we are not sure that there is here at TrialSite News, but we are committed to clinical research transparency with focus ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee